Home/Filings/4/0001835458-25-000003
4//SEC Filing

Ragosa Mark 4

Accession 0001835458-25-000003

CIK 0001730430other

Filed

Oct 29, 8:00 PM ET

Accepted

Oct 30, 4:47 PM ET

Size

17.2 KB

Accession

0001835458-25-000003

Insider Transaction Report

Form 4
Period: 2025-10-28
Ragosa Mark
CHIEF FINANCIAL OFFICER
Transactions
  • Sale

    Class A Ordinary Share

    2025-10-28$41.00/sh100$4,10031,086 total
  • Exercise/Conversion

    Share Option

    2025-10-2810019,900 total
    Exercise: $30.93Exp: 2028-09-19Class A Ordinary Share (100 underlying)
  • Exercise/Conversion

    Class A Ordinary Share

    2025-10-28$30.93/sh+100$3,09331,186 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.
  • [F2]The option is fully vested and exercisable.

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

Entity typeother

Related Parties

1
  • filerCIK 0001835458

Filing Metadata

Form type
4
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 4:47 PM ET
Size
17.2 KB